Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Tuberculosis
•
Pulmonology
•
Pulmonary Infections
How do you approach a positive IGRA in a patient with idiopathic NSIP needing a prolonged course of corticosteroid therapy and a prior history MAC in a single sputum culture?
Related Questions
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
Do you integrate inhaled colistimethate sodium into existing treatment regimens for patients with bronchiectasis and PSAR infection?
What is the recommended fungal workup in an immunocompromised patient after 5 days of persistent fever?
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
Have you incorporated the use of MycoTOX profiles into your clinical practice and, if so, in what capacity?
